chronic%20obstructive%20pulmonary%20disease
CHRONIC OBSTRUCTIVE PULMONARY DISEASE

Chronic obstructive pulmonary disease (COPD) is an inflammatory respiratory disease characterized by reversible airflow limitation.

The patient usually have chronic cough, sputum production or dyspnea with or without history of risk factors for the disease.

The chronic airflow limitation is caused by a combination of small airways disease and parenchymal destruction.

It is a preventable & treatable disease.

Monitoring

Prior to discharge from the hospital, check the patient based on the following criteria:

  • Able to use long-acting either beta2-agonists &/or anticholinergics with or without inhaled corticosteroids
  • Inhaled beta2-agonist is needed every 4 hours or less frequently
  • Able to walk across the room (if previously ambulatory)
  • Able to eat & sleep without frequent interruptions due to breathing difficulty
  • Clinically stable for 12-24 hours
  • ABG stable for 12-24 hours
  • Patient & caregiver adequately understand correct medication use
  • Home care arrangements (eg O2 delivery) are in place
  • Patient, family & physician are confident that patient can manage well

Follow Up

  • A follow-up assessment must be carried out within 4-6 weeks following discharge from hospital for exacerbations
  • Check patient’s ability to cope in his environment
  • Measure FEV1
  • Check inhaler technique
  • Check understanding & ability to follow of treatment regimen
  • Assess need for long-term O2 therapy &/or home nebulizer for patients with very severe COPD
  • Check status of comorbidities
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.
Tristan Manalac, 27 Jun 2017
Prolonged sleep duration is an independent predictor of higher incident atrial fibrillation (AF) risks in a Chinese population, reports a new prospective, population-based study.
Rachel Soon, 01 Jun 2017

Pirfenidone, an oral antifibrotic and anti-inflammatory agent, is now indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in Malaysia.